Know Cancer

or
forgot password

Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor


Phase 3
12 Years
N/A
Not Enrolling
Both
Cushing's Disease, Corticotroph Adenoma

Thank you

Trial Information

Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor


Inclusion Criteria:



- Patient with Cushing's disease uncured biochemically after pituitary surgery with
adenoma on histopathology

Exclusion Criteria:

- Patient's intolerance to drug or known sensitivity to ergot derivatives

- Pregnancy, lactation or female wishing to be pregnant

- Any serious medical illness

- Patient on any drugs known to have an interaction with cabergoline including
antihypertensives like reserpine and methyl dopa, neuroleptics, metoclopramide, etc

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response in term of mid night cortisol < 5.0 mcg/dl and/or Standard two day dexamethasone suppression test < 1.8 mcg/dl

Principal Investigator

Nalini S Shah, DM

Investigator Role:

Principal Investigator

Investigator Affiliation:

Seth GSMC and KEM hospital, Mumbai

Authority:

India: Drugs Controller General of India

Study ID:

EC/104/2005

NCT ID:

NCT00889525

Start Date:

November 2007

Completion Date:

Related Keywords:

  • Cushing's Disease
  • Corticotroph Adenoma
  • Cabergoline
  • Adenoma
  • Cushing Syndrome
  • Pituitary ACTH Hypersecretion
  • Pituitary Neoplasms
  • ACTH-Secreting Pituitary Adenoma

Name

Location